Johnson & Johnson reported a 6% revenue increase to $25.4 billion in Q3 2026, but earnings per share (EPS) declined 7.5% year-on-year, causing the stock to fall 5%. The company set aside $5.5 billion to resolve talc litigation, aiming for 95% plaintiff participation, though legal uncertainties remain. Growth in the Innovative Medicines division offset patent losses, but the MedTech segment underperformed, leading to plans to spin off its orthopedics unit. Despite challenges, JNJ remains a solid long-term hold, though less attractive currently due to MedTech struggles and no exposure to GLP-1 drugs.
Johnson & Johnson trades at USD 246.65 on Pluang as of Oct 14, 2026 00:21 WIB, down 6.48% in one day. The stock's market cap is $635.56 billion, with a 52-week range between $186.00 and $278.43. Pluang data shows 84% of orders are sell, reflecting cautious investor sentiment amid recent challenges.
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine divisio...
Johnson & Johnson increased its 2026 sales forecast to $101.2 billion and raised adjusted EPS guidance to $11.10 after reporting a 6% operational sales growth in Q3. The growth was driven by strong performance in its Innovative Medicine division, esp...
Johnson & Johnson's TREMFYA (guselkumab) demonstrated consistent combined fistula remission rates of up to 28% at Week 24 in adults with Crohn's disease and perianal fistula, outperforming placebo at 10%. New Phase 3 subgroup analyses from the FUZION...
Johnson & Johnson announced three-year data from Phase 3 GALAXI 2 and 3 studies showing TREMFYA (guselkumab) provides durable clinical remission rates up to 94% and endoscopic remission up to 61% in adults with moderately to severely active Crohn's d...
